Abstract 1643P
Background
Neoadjuvant (m)FOLFIRINOX has been established as one of standard therapy for borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC). Recently, its use has been expanded to resectable pancreatic cancer (RPC), but large pragmatic studies, particularly in Asia, to show the implication of localized pancreatic adenocarcinoma are still lacking.
Methods
This retrospective study included 781 patients with localized pancreatic adenocarcinoma who received (m)FOLFIRINOX as initial therapy in Asan Medical Center, Seoul, Korea, between DEC 2017 and DEC 2020.
Results
The median age was 62 years, and 341 (43.8%) patients were female. According to the NCCN criteria, 131 (16.8%), 326 (41.9%), and 321 (41.3%) patients had RPC, BRPC and LAPC, respectively. The objective response rates were 22.1%, 16.3%, and 15.0%, respectively. The curative-intent resection (R0 or R1) was performed in 94 (71.8%) patients of the RPC group, 137 (42.0%) patients of the BRPC group, and 40 (12.5%) patients of the LAPC group; patients who underwent curative resection, the R0 resection rates were similar among three groups (86.2%, 86.1%, and 80.0%, respectively). There were 11 patients who achieved surgery following salvage chemotherapy after progression on initial (m)FOLFIRINOX. The median overall survival (OS) was 28.1 months (95% CI, 22.7–33.5) for RPC, 22.0 months (95% CI, 19.8–24.1) for BRPC, and 20.3 months (95% CI, 18.7–21.9) for LAPC (p<0.001). In each resectability group, median OS was significantly better in patients with surgical resection (RPC, 41.6 vs 14.5 months, p<0.001; BRPC, 37.3 vs 14.7, p<0.001; LAPC, 51.4 vs 18.5 months, p<0.001). In multivariate analysis, female gender, RPC, baseline CA 19-9 < median (118.7 U/mL), objective response (CR or PR), and curative-intent surgery were significantly associated with better OS.
Conclusions
This large retrospective cohort study provides the realistic key clinical outcome data such as resection rates, survival outcomes and prognostic factors in RPC, BRPC and LAPC treated with front-line (m)FOLFIRINOX.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22